Trimetaphan Camsilate

樟磺咪芬

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameTrimetaphan Camsilate
Drug Alias Name咪噻芬Trimetaphan CamsylateTrimethaphan camsylate阿芳那特Arfonad
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNeuronal acetylcholine receptor; alpha3/beta4 antagonists
TargetsNeuronal acetylcholine receptor; alpha3/beta4
Therapy Area/IndicationsInsulin ResistanceHypertensionVascular Diseases +[5] 
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1954/04/26
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesVanderbilt University
Inactive CompaniesF. Hoffmann-La Roche LtdVanderbilt University Medical Center
Active IndicationsHypotension, OrthostaticMultiple System Atrophy
Inactive IndicationsInsulin ResistanceHypertensionVascular Diseases

Other Information

ATC CodeC02BA01
Related LinksWikipediaDrugBankKEGG